Biogen and Ionis Pharmaceuticals soar on a new muscle-disorder drug for babies, CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
"Fast Money Halftime Report" traders Jon Najarian and Pete Najarian discuss unusual activity with FireEye and Abbott.
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
Thursday looms large as the busiest day of earnings, with pharma, consumer products, big oil, financials and autos reporting.
Bayer surpassed second-quarter earnings expectations and raised its guidance for the year on strong gains in stroke prevention pill Xarelto.
In the face of a potential rate hike by the Federal Reserve, and the presidential conventions, where should you put your money? John Augustine, The Huntington Trust chief investment officer, and Brad McMillan, Commonwealth Financial Network chief investment officer, share their strategies.
People complaining about how risky the stock market is ought to take a look at the so-called safety of today's bond market.
Stephanie Link, TIAA Global Asset Management, and the FMHR traders find value in the market.
CNBC's Dominic Chu discusses where an investor can find protection amidst the market turmoil from the Brexit vote.
Jim Cramer described the energy surrounding a possible Brexit as "hysteria."
Jim Cramer wasn't freaked out by this bold event in the oil patch.
Jim Cramer lays out his game plan for Brexit action next week, and has his eye on black gold to hold the key on when to move.
The "FMHR" traders discuss the biotech and pharmaceuticals trade and give their best bets for stocks.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
Richard Ross, Managing Director and Head of Technical Analysis at Evercore ISI, takes a technical look at three stocks he says are about to break out.
Jim Cramer sees signs everywhere that the worst is over for pharma.
Jim Cramer sees signs everywhere that the worst is over for pharma. He goes down his playbook of pharma signs, and how to play it.
Some 30 American companies were recognized for their efforts to boost diversity and inclusion.
It's the busiest earnings week of the quarter. The HR experts give a preview